北京军区总医院基因导向的个体化给药项目及其临床应用  

Gene-directed personalized medication and clinical practice in the General Hospital of Beijing Military Command of PLA

作　　者：边佳明[1] 丁媛媛[1] 杨凡[1] 张梅[1] 许景峰[1] 

机构地区：[1]北京军区总医院药理科,北京100700

出　　处：《药学服务与研究》2014年第3期161-165,共5页Pharmaceutical Care and Research

摘　　要：本文介绍了北京军区总医院药理科应用焦磷酸测序基因分型技术开展的多种个体化给药基因检测项目,包括:β1肾上腺素受体基因和CYP2 D6基因;CYP2C19基因;维生素K环氧化物还原酶复合物1基因和CYP2C9基因;巯嘌呤甲基转移酶基因;表皮生长因子受体基因;IL28B基因;O6-甲基鸟嘌呤-DNA-甲基转移酶基因;SLCO1B1基因;HLA-B*1502,HLA-B*5801等位基因等。这些基因检测项目的实施为判断遗传因素对临床疗效及不良反应的影响提供了依据。This paper describes detections of gene-directed personalized medication based on pyrophosphoric acid sequencing typing of genes in the Department of Pharmacology, General Hospital of Beijing Military Command of PLA, inclu- ding β1 adrenergic receptor （β1 AR） and CYP2D6 genes, CYP2C19 gene; vitamin K epoxide reductase complex suhunit 1 （VKORC1） and CYP2C9 genes ; thiopurine methyhransferase （TPMT） gene; epidermal growth factor receptor （EGFR） gene ; IL28B gene; O6-methylguanine-DNA methyltransferase （MGMT） gene; SLCO1B1 gene; HLA-B ＊ 1502 and HLA-B ＊ 5801 alleles,etc. The implementation of these gene detection programs could provide sound evidence for the prediction of clinical efficacy and adverse effects of drugs possibly induced by genetic factors.

关 键 词：药物遗传学 药物基因组学 个体化给药 PCR检验 

分 类 号：R968[医药卫生—药理学]